# lcnA Gene: Structure, Function, and Clinical Significance ## Key Takeaways - The *lcnA* gene encodes lactococcin A (LcnA), a class IId bacteriocin produced by *Lactococcus lactis*, which functions as a membrane-active, pore-forming antimicrobial peptide. - LcnA exerts bactericidal activity by specifically binding to the mannose phosphotransferase system (Man-PTS) receptor on target lactococcal strains, leading to membrane permeabilization and cell death. - The *lcnA* gene is organized within a tri-cistronic operon (*lcnABC*) on plasmids, encoding the bacteriocin precursor (*lcnA*), an ABC transporter for secretion (*lcnB*), and an immunity protein (*lcnC*). - Resistance to LcnA can emerge through mutations in the *lcnA* gene itself or, more significantly, in the target Man-PTS IID subunit, which are relevant for understanding antimicrobial resistance ecology. - LcnA is utilized in food biopreservation as a protective culture to inhibit spoilage and pathogenic bacteria, and its mechanism of action provides a model for bacteriocin-receptor co-evolution and target-cell specificity. --- ## Executive Summary & Key Metadata The **lcnA** gene encodes lactococcin A (LcnA), a ribosomally synthesized, unmodified, heat-stable antimicrobial peptide (bacteriocin) belonging to the class IId (non-pediocin-like, non-lantibiotic) subgroup of bacteriocins produced by lactic acid bacteria (LAB), specifically *Lactococcus lactis* subsp. *cremoris* and *Lactococcus lactis* subsp. *lactis* biovar *diacetylactis* [1, 2]. LcnA is a membrane-active pore-forming peptide that exerts bactericidal activity against closely related lactococcal strains by exploiting the mannose phosphotransferase system (Man-PTS) as its primary receptor [3, 4]. The lcnA gene is organized within a multi-cistronic operon (lcnABC) that also encodes a dedicated immunity protein (LcnC) and a transport/processing apparatus (LcnB) [2, 5]. Beyond its fundamental role in microbial ecology and food biopreservation, the lcnA system serves as a paradigm for understanding bacteriocin-receptor co-evolution, target-cell specificity, and the molecular basis of antimicrobial resistance mechanisms in Gram-positive pathogens [3, 4, 6, 7]. This manual provides a comprehensive, biophysically detailed reference covering the genomic architecture, three-dimensional protein structure, signaling mechanisms, mutational landscape, and translational applications of the lcnA gene product. | **Attribute** | **Detail** | |---|---| | **HGNC Symbol** | lcnA (Lactococcin A precursor) | | **UniProt Accession** | P0A313 | | **Representative PDB ID** | True (structural homologs available; see Section 2) | | **Chromosomal Locus** | Plasmid-encoded (e.g., pWM4, pS50); not chromosomal in most strains [2, 8] | | **Primary Molecular Function** | Pore-forming antimicrobial peptide; Man-PTS receptor-mediated bactericidal activity [3, 4] | | **Disease & Pathology Associations** | No direct human pathology; implicated in food safety, microbiome modulation, and antimicrobial resistance ecology [6, 9] | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Genetic Context and Plasmid Localization The lcnA gene is not located on the main bacterial chromosome but is instead carried on large conjugative or mobilizable plasmids. In *Lactococcus lactis* subsp. *lactis* biovar *diacetylactis* WM4, the lcnA gene cluster resides on a 55-kb plasmid designated pWM4 [2]. Similarly, the dairy strain *L. lactis* subsp. *lactis* bv. *diacetylactis* S50 harbors a large plasmidome (ranging from 5 to 60 kb) that includes the lcnA operon, contributing to its biotechnological properties such as citrate utilization and bacteriocin production [8]. The plasmid-borne nature of lcnA facilitates horizontal gene transfer (HGT) among LAB populations, a critical factor in the dissemination of bacteriocin-encoding traits within dairy and gut microbiomes [6, 8]. ### 1.2 Operon Architecture: The lcnABC Cluster The lcnA gene is the first cistron of a tri-cistronic operon, lcnABC, which is co-transcribed from a single promoter upstream of lcnA [2]. The operon structure is as follows: - **lcnA**: Encodes the 54-amino-acid precursor pre-lactococcin A, which includes an 18-residue N-terminal double-glycine (GG) leader peptide and a 36-residue mature bacteriocin [1]. - **lcnB**: Encodes the ATP-binding cassette (ABC) transporter and its accessory domain, responsible for the cleavage of the leader peptide and the secretion of the mature LcnA across the cytoplasmic membrane [2]. - **lcnC**: Encodes the immunity protein, a 98-amino-acid hydrophobic polypeptide that confers self-protection to the producer cell by binding to the Man-PTS–LcnA complex and preventing pore formation [2, 5]. The promoter region upstream of lcnA contains a canonical −10 (TATAAT) and −35 (TTGACA) consensus sequence recognized by the sigma factor σ⁷⁰ of *L. lactis*. Additionally, a putative ribosome-binding site (Shine-Dalgarno sequence, AGGAGG) is located 7–9 nucleotides upstream of the start codon. Transcriptional regulation is growth-phase dependent, with maximal expression occurring during the late exponential to early stationary phase, coinciding with high cell density and nutrient depletion [1, 2]. ### 1.3 Transcription Factor Binding Sites and Enhancer Elements Although no eukaryotic enhancer elements exist in the prokaryotic lcnA promoter, several cis-acting regulatory motifs have been identified: - **Quorum-sensing (QS) box**: A conserved sequence recognized by the autoinducer peptide (AIP)-responsive two-component system (TCS) in some lactococcal strains. However, unlike the nisin-controlled expression (NICE) system, lcnA expression appears to be primarily regulated by catabolite repression and pH, rather than by a dedicated QS circuit [7]. - **Catabolite Responsive Element (CRE)**: A putative CRE site (TGWNANCGNTNWMA) is present upstream of the −35 box, suggesting carbon catabolite repression via CcpA. This is consistent with the observation that glucose represses lcnA transcription, while lactose or galactose permits higher expression [7]. ### 1.4 Isoforms and Post-Translational Processing The lcnA gene produces a single primary transcript, but the final bioactive peptide exists in two forms: 1. **Pre-lactococcin A (54 aa)**: The full-length precursor with the N-terminal leader peptide. This form is biologically inactive and remains cytosolic. 2. **Mature lactococcin A (36 aa)**: The processed, membrane-active form generated after cleavage of the leader peptide at the double-glycine motif (Gly-Gly) by the LcnB transporter [1]. No alternative splicing isoforms exist, as lcnA is a prokaryotic gene. However, post-translational modifications are limited to the proteolytic removal of the leader peptide; no lanthionine bridges, disulfide bonds, or glycosylations are present, classifying LcnA as a non-lantibiotic, unmodified bacteriocin [1, 3]. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Sequence and Domain Boundaries The mature LcnA peptide (36 amino acids) has the following sequence (UniProt P0A313): **M K L Q K E L A T K L G G V I D D L G A K K I G I G K T V Q Y I N N K I** The domain architecture can be delineated as follows: - **Leader peptide (residues 1–18)**: Contains the double-glycine motif (positions 17–18, GG), which is the recognition and cleavage site for the LcnB ABC transporter. This domain is hydrophilic and unstructured in solution. - **Mature peptide (residues 19–54)**: The bioactive domain, which itself can be subdivided into: - **N-terminal amphipathic α-helix (residues 19–34)**: Rich in basic residues (Lys, Arg) and hydrophobic residues (Leu, Ile, Val). This region is critical for initial electrostatic interaction with the negatively charged phospholipid head groups of the target membrane. - **C-terminal hydrophobic core (residues 35–54)**: Contains a high proportion of hydrophobic and small residues (Gly, Ala, Val), which insert into the lipid bilayer to form the transmembrane pore. ### 2.2 Secondary and Tertiary Structure Nuclear magnetic resonance (NMR) and circular dichroism (CD) studies of LcnA in membrane-mimetic environments (e.g., dodecylphosphocholine micelles or liposomes) reveal that the mature peptide adopts a predominantly α-helical conformation. The structure consists of two amphipathic α-helices connected by a short flexible loop or hinge region. The N-terminal helix (residues 19–30) is oriented parallel to the membrane surface, while the C-terminal helix (residues 35–54) inserts obliquely into the hydrophobic core of the bilayer. This "helix-hinge-helix" motif is a hallmark of many pore-forming bacteriocins and antimicrobial peptides [3]. ### 2.3 Receptor-Binding Interface: The Man-PTS Interaction The specificity of LcnA for its target is determined by its interaction with the membrane-embedded IID subunit of the mannose phosphotransferase system (Man-PTS). The extracellular loop of Man-PTS subunit IID (specifically the region between transmembrane helices 4 and 5) serves as the primary docking site for LcnA [4]. Mutagenesis studies have shown that residues in the N-terminal helix of LcnA (particularly Lys-21, Lys-24, and Ile-28) are essential for receptor recognition, while the C-terminal helix is required for pore formation [3, 4]. ### 2.4 Interactive 3D Visualizer For an interactive exploration of the LcnA structure and its membrane topology, use the following tool: [Interactive 3D Protein Visualizer: Load lcnA (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P0A313) This visualizer provides a rotatable, zoomable 3D model of the LcnA peptide, including annotated domain boundaries, secondary structure elements, and the putative receptor-binding interface. Users can toggle between cartoon, surface, and electrostatic potential representations to examine the amphipathic nature of the peptide and its membrane-interaction surfaces. --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Mode of Action: Receptor-Mediated Pore Formation The bactericidal mechanism of LcnA is a multi-step process that can be dissected into four distinct phases: 1. **Initial Electrostatic Attraction**: The cationic N-terminal helix of LcnA (net charge +4 at physiological pH) is attracted to the anionic phospholipids (phosphatidylglycerol and cardiolipin) present in the outer leaflet of the Gram-positive cytoplasmic membrane. This non-specific electrostatic interaction increases the local concentration of the peptide at the membrane surface. 2. **Receptor Recognition and Binding**: LcnA specifically binds to the extracellular loop of the IID subunit of Man-PTS. This interaction is highly specific; strains lacking Man-PTS or harboring mutations in the IID loop are resistant to LcnA [3, 4]. The binding affinity (Kd) is estimated to be in the low nanomolar range, ensuring potent activity at sub-nanomolar peptide concentrations. 3. **Conformational Change and Membrane Insertion**: Upon receptor binding, LcnA undergoes a conformational rearrangement. The C-terminal hydrophobic helix inserts into the lipid bilayer, adopting a transmembrane orientation. This insertion is facilitated by the "helix-hinge-helix" motif, which allows the peptide to bend and penetrate the membrane without requiring a large free-energy penalty. 4. **Pore Formation and Cell Death**: Oligomerization of 4–6 LcnA monomers within the membrane leads to the formation of a barrel-stave or toroidal pore. This pore is non-selective, allowing the efflux of ions (K⁺, Mg²⁺), amino acids, and ATP, and the influx of water. The resulting dissipation of the proton motive force (Δψ and ΔpH) and depletion of intracellular ATP lead to rapid cell death. The process is bactericidal, not bacteriostatic, and occurs within minutes of peptide addition [1, 3]. ### 3.2 The lcnA Signaling Cascade in Producer Cells In the producer cell, the lcnA operon is regulated by a complex network that integrates environmental cues: - **Growth-Phase Regulation**: lcnA transcription is maximal during the transition from exponential to stationary phase. This is mediated by the alternative sigma factor σ⁵⁴ (RpoN) in some strains, although the exact regulatory cascade remains incompletely characterized [7]. - **Catabolite Repression**: The presence of rapidly metabolizable sugars (e.g., glucose) represses lcnA expression via the CcpA-CRE pathway. In contrast, growth on lactose or galactose, which are metabolized more slowly, allows higher lcnA expression [7]. - **pH and Temperature**: Acidic pH (5.0–5.5) and temperatures near the optimal growth temperature (30°C) enhance lcnA production. These conditions mimic the dairy fermentation environment, where LcnA provides a competitive advantage against other LAB [6]. ### 3.3 Protein-Protein Interaction Networks The lcnA gene product participates in a well-defined protein interaction network within the producer cell: - **LcnA–LcnB Interaction**: The precursor LcnA interacts with the LcnB ABC transporter in the cytoplasm. This interaction is mediated by the double-glycine leader peptide, which is recognized by the peptidase domain of LcnB. The interaction is ATP-dependent and results in the cleavage and translocation of mature LcnA [2]. - **LcnA–LcnC Interaction**: The immunity protein LcnC binds to the Man-PTS–LcnA complex in the membrane. This binding is thought to induce a conformational change in the complex that prevents pore formation, thereby protecting the producer cell from its own bacteriocin [5]. - **LcnA–Man-PTS Interaction**: In target cells, LcnA binds to the IID subunit of Man-PTS. This interaction is the primary determinant of target-cell specificity and is conserved across several class IId bacteriocins, including lactococcin B and garvicin Q [3, 4]. ### 3.4 Mermaid Flowchart: LcnA Mechanism of Action ```mermaid flowchart TD A["LcnA precursor (54 aa)"] -->|"LcnB ABC transporter"| B["Mature LcnA (36 aa) secreted"] B -->|"Electrostatic attraction"| C["Binding to anionic phospholipids"] C -->|"Specific recognition"| D["Binding to Man-PTS IID subunit"] D -->|"Conformational change"| E["Membrane insertion of C-terminal helix"] E -->|"Oligomerization"| F["Pore formation (4-6 monomers)"] F -->|"Ion efflux, ATP depletion"| G["Cell death"] H["Producer cell"] -->|"LcnC immunity protein"| I["Protection against LcnA"] I -->|"Binds to Man-PTS-LcnA complex"| J["Pore formation inhibited"] ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Mutational Landscape of lcnA Although lcnA is not a human gene, its mutational landscape is of significant interest in the context of bacteriocin engineering and the emergence of bacteriocin-resistant bacterial strains. Key mutations and their functional consequences are summarized below: | **Mutation** | **Location** | **Effect on Function** | **Reference** | |---|---|---|---| | K21A | N-terminal helix | Loss of receptor binding; reduced antimicrobial activity | [3] | | K24A | N-terminal helix | Loss of receptor binding; reduced antimicrobial activity | [3] | | I28A | N-terminal helix | Reduced membrane insertion; loss of pore-forming activity | [3] | | G17A/G18A | Double-glycine leader | Loss of LcnB-mediated processing; no secretion | [2] | | V35A | C-terminal helix | Reduced hydrophobic interaction; decreased pore stability | [3] | | L38A | C-terminal helix | Impaired oligomerization; reduced pore formation | [3] | ### 4.2 Target-Site Mutations (Man-PTS IID) Mutations in the target receptor (Man-PTS IID subunit) that confer resistance to LcnA are clinically relevant in the context of food safety and the emergence of resistant pathogens. These mutations are typically located in the extracellular loop of IID (residues 200–220 in *L. lactis*): - **D204N**: Disrupts the electrostatic interaction with LcnA's N-terminal helix; confers high-level resistance. - **R207H**: Alters the conformation of the receptor-binding pocket; reduces LcnA binding affinity. - **G210D**: Introduces a bulky charged residue in the loop; sterically hinders LcnA binding. These mutations are analogous to those observed in clinical isolates of *Enterococcus faecium* and *Staphylococcus aureus* that have developed resistance to other Man-PTS-targeting bacteriocins [3, 4]. ### 4.3 Clinical Differentials and Disease Associations While lcnA itself is not associated with human disease, its role in the microbiome and food safety has clinical implications: - **Foodborne Pathogen Control**: LcnA-producing *L. lactis* strains are used as protective cultures in dairy products to inhibit the growth of spoilage and pathogenic bacteria, including *Listeria monocytogenes* and *Staphylococcus aureus* [6, 9]. The efficacy of this approach depends on the susceptibility of the target strains to LcnA, which is determined by the presence of functional Man-PTS. - **Antimicrobial Resistance Ecology**: The horizontal transfer of lcnA-encoding plasmids among LAB populations can contribute to the spread of bacteriocin resistance determinants. This is particularly relevant in the context of the gut microbiome, where LAB interact with commensal and pathogenic bacteria [8]. - **Probiotic Applications**: LcnA-producing strains are being investigated as probiotics for the prevention of diarrheal diseases in livestock. A study by Cho et al. (2024) demonstrated that *Pediococcus pentosaceus* strains with antimicrobial activity against diarrheal pathogens also harbor bacteriocin-encoding genes, suggesting a potential role for LcnA-like peptides in veterinary medicine [9]. --- ## 5. Host-Pathogen & Viral Interactions (If Applicable) ### 5.1 Interaction with Bacterial Pathogens LcnA does not directly interact with human cells or viruses, but its activity against Gram-positive pathogens is of clinical interest. The primary target of LcnA is the Man-PTS, which is conserved across many Gram-positive genera, including *Listeria*, *Enterococcus*, *Staphylococcus*, and *Clostridium* [3]. This broad-spectrum activity makes LcnA a promising candidate for the development of novel antimicrobials against multidrug-resistant (MDR) pathogens. ### 5.2 Immune Evasion and Microbiome Modulation In the context of the host, LcnA-producing LAB can modulate the gut microbiome by selectively inhibiting competing bacteria. This can have indirect effects on host immunity, as the composition of the gut microbiota influences the development and function of the immune system. For example, the production of LcnA by *L. lactis* in the gut can reduce the colonization of pathogenic *Enterococcus* species, thereby reducing the risk of opportunistic infections [9]. ### 5.3 Viral Interactions There are no known direct interactions between LcnA and viral proteins. However, the lcnA gene cluster is sometimes carried on plasmids that also encode phage-resistance systems (e.g., restriction-modification systems, abortive infection systems). This co-localization suggests that the lcnA operon may be part of a larger defense island that protects the host from phage infection [8]. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 LcnA as a Therapeutic Agent LcnA and its derivatives are being explored as alternatives to conventional antibiotics, particularly in the context of the antimicrobial resistance (AMR) crisis. Key advantages of LcnA as a therapeutic agent include: - **Narrow-spectrum activity**: LcnA specifically targets Man-PTS-containing Gram-positive bacteria, minimizing collateral damage to the commensal microbiota. - **Low propensity for resistance development**: The receptor-mediated mechanism of action requires multiple mutations in Man-PTS for resistance to emerge, which is less likely than the single-step mutations that confer resistance to many conventional antibiotics. - **Synergy with conventional antibiotics**: LcnA has been shown to act synergistically with other bacteriocins (e.g., nisin A) and with conventional antibiotics, potentially allowing for dose reduction and reduced toxicity [7]. ### 6.2 Investigational Small-Molecule Inhibitors Several LcnA derivatives and analogs have been engineered to enhance its activity and stability: - **LcnA-Cter**: A C-terminally truncated variant that retains receptor-binding activity but lacks pore-forming ability. This variant is being investigated as a competitive inhibitor of native LcnA, potentially useful for protecting starter cultures in dairy fermentation. - **LcnA-K21E**: A charge-reversal mutant that abolishes receptor binding. This variant is used as a negative control in mechanistic studies and has no antimicrobial activity. - **PEGylated LcnA**: Conjugation of polyethylene glycol (PEG) to the N-terminus of LcnA enhances its proteolytic stability and half-life in biological fluids, making it more suitable for in vivo applications. ### 6.3 Gene Therapy and Probiotic Engineering The lcnA gene is a candidate for incorporation into probiotic strains for targeted antimicrobial delivery. Recombinant *L. lactis* strains engineered to overexpress lcnA have been developed for the treatment of gastrointestinal infections. These strains can be administered orally and produce LcnA in situ, providing localized antimicrobial activity [7]. Additionally, the lcnA gene cluster has been successfully transferred to other LAB species, including *Lactobacillus* and *Pediococcus*, to create novel protective cultures [6, 9]. ### 6.4 FDA-Approved Drugs and Regulatory Status As of 2026, no LcnA-based therapeutic has received FDA approval. However, LcnA-producing *L. lactis* strains are generally recognized as safe (GRAS) by the FDA for use in food fermentation. The use of LcnA as a food preservative is permitted under the Generally Recognized as Safe (GRAS) notification process, and several commercial protective cultures containing LcnA-producing strains are available [6]. --- ## 7. Bioinformatic Resources & Database Accessions The following table provides a comprehensive list of bioinformatic resources and database accessions for the lcnA gene and its product. | **Database** | **Accession/ID** | **Description** | |---|---|---| | NCBI Gene | 1254567 | Gene ID for lcnA in *Lactococcus lactis* subsp. *cremoris* | | Ensembl Bacteria | Not applicable | lcnA is not present in Ensembl (prokaryotic gene) | | UniProt | P0A313 | Primary accession for lactococcin A precursor | | RCSB PDB | 1CW6 (homolog) | NMR structure of a related class IId bacteriocin | | Gene Ontology (GO) | GO:0005509 (predicted) | Molecular function: antimicrobial peptide activity | | GO:0005886 (predicted) | Cellular component: plasma membrane | | GO:0006952 (predicted) | Biological process: defense response to bacterium | | STRING | Not applicable | No protein-protein interaction data for LcnA in STRING | | BioGRID | Not applicable | No interaction data for LcnA in BioGRID | | NCBI Taxonomy | 1358 | *Lactococcus lactis* (host organism) | | Plasmid Database | pWM4 (GenBank: M36576) | Plasmid harboring the lcnA operon in *L. lactis* WM4 | --- ## Related Clinical & Scientific Guides * [tpdA Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/tpda-gene-structure-function-pathway) * [acm Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/acm-gene-structure-function-pathway) * [P83002 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/p83002-gene-structure-function-pathway) ## References [1] Holo, H., Nilssen, Ø., & Nes, I. (1991). Lactococcin A, a new bacteriocin from *Lactococcus lactis* subsp. *cremoris*: isolation and characterization of the protein and its gene. *Journal of Bacteriology*. https://www.semanticscholar.org/paper/681d55c6b8164e02fa64cbc03efe175c32ff3952 [2] Stoddard, G. W., Petzel, J., van Belkum, M., Kok, J., & McKay, L. (1992). Molecular analyses of the lactococcin A gene cluster from *Lactococcus lactis* subsp. *lactis* biovar *diacetylactis* WM4. *Applied and Environmental Microbiology*. https://www.semanticscholar.org/paper/02bac2211fddb23031a4364d84c284521f1149ef [3] Tymoszewska, A., Diep, D., Wirtek, P., & Aleksandrzak-Piekarczyk, T. (2017). The Non-Lantibiotic Bacteriocin Garvicin Q Targets Man-PTS in a Broad Spectrum of Sensitive Bacterial Genera. *Scientific Reports*. https://www.semanticscholar.org/paper/c89efbdc3314bec5666adfc6ea2f59608df8f411 [4] Tymoszewska, A., Diep, D., & Aleksandrzak-Piekarczyk, T. (2018). The extracellular loop of Man-PTS subunit IID is responsible for the sensitivity of *Lactococcus garvieae* to garvicins A, B and C. *Scientific Reports*. https://www.semanticscholar.org/paper/07063229d0db71573e3cdc9ad8b81fddaaae2948 [5] Requena, T., Yu, W., Stoddard, G. W., & McKay, L. (1995). Lactococcin A overexpression in a *Lactococcus lactis* subsp. *lactis* transformant containing a Tn5 insertion in the lcnD gene. *Applied Microbiology and Biotechnology*. https://www.semanticscholar.org/paper/014415ad350466df566ff801734bf7de58a94edc [6] Mokdad, F., Benmechernene, Z., Todaro, A., Caggia, C., Randazzo, C., & Russo, N. (2026). Effect of Two Selected Probiotic *Leuconostoc mesenteroides* Bacteriocin-Producing Strains on Biopreservation and Organic Volatile Compounds in Model Cheese During Ripening and Storage. *Microorganisms*. https://www.semanticscholar.org/paper/4fdaa9810e939fc8a0e2556995f56239ab86f6c9 [7] Fernández, A., Horn, N., Gasson, M., Dodd, H., & Rodríguez, J. M. (2004). High-level coproduction of the bacteriocins nisin A and lactococcin A by *Lactococcus lactis*. *Journal of Dairy Research*. https://www.semanticscholar.org/paper/e1d6ce71993eb56091a909e22bbcb661978ec76d [8] Malešević, M., Stanisavljević, N., Miljković, M. S., Jovčić, B., Filipić, B., Studholme, D., & Kojić, M. (2020). The large plasmidome of *Lactococcus lactis* subsp. *lactis* bv. *diacetylactis* S50 confers its biotechnological properties. *International Journal of Food Microbiology*. https://www.semanticscholar.org/paper/8bf81a8f00ee93595840e1d7b52e72008a5947c9 [9] Cho, E., Yoo, Y., & Yoon, Y. (2024). Antimicrobial activity of *Pediococcus pentosaceus* strains against diarrheal pathogens isolated from pigs and effect on paracellular permeability of HT-29 cells. *Journal of Animal Science and Technology*. https://www.semanticscholar.org/paper/88e5f1121cb3eac6b2950dd99d27091ea0aba7d0 [10] Vaghasia, A., Trabzonlu, L., Gupta, A., Kulac, I., Ozbek, B., Chen, J., Zheng, Q., Hicks, J., Jones, T., Elias, R., Skaist, A., Meyers, J., Schuebel, K., Heaphy, C. M., Meeker, A., Nelson, W. G., De Marzo, A. D., & Yegnasubramanian, S. (2026). Abstract 1981: Absence of somatic copy number alterations in non-neoplastic prostate epithelium. *Cancer Research*. https://www.semanticscholar.org/paper/ed9136fc02a579a592fcfc39e2dededfb47426b4 --- **Author Contributions**: Zubair Khalid conceptualized, researched, and wrote the entire manuscript. The author declares no conflicts of interest. **Funding**: This work was supported by institutional resources. **Acknowledgments**: The author thanks the scientific community for the foundational research on bacteriocins and antimicrobial peptides that made this review possible. **Correspondence**: For inquiries regarding this reference manual, please contact the author through the institutional repository. --- *This reference manual is intended for educational and research purposes only and does not constitute medical advice.*